TIDMBXP
RNS Number : 5178S
Beximco Pharmaceuticals Ltd
06 November 2023
6 November 2023
BEXIMCO PHARMACEUTICALS LIMITED
AGM Notification
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, today announces that the
forty-seventh Annual General Meeting of Shareholders (AGM) of
Beximco Pharma will be held virtually on Thursday 28 December 2023
at 10.30 a.m. to transact the following business:
AGENDA
1. To receive, consider and adopt the Audited Financial
Statements of the Company for the year ended on 30 June 2023
together with reports of the Auditors and the Directors
thereon.
2. To declare 35% Cash Dividend.
3. To elect Directors.
4. To Approve the re-appointment of Independent Director.
5. To appoint Auditor for the year 2023-2024 and to fix their remuneration.
6. To appoint Corporate Governance Compliance Auditor for the
year 2023-2024 and to fix their remuneration.
By order of the Board
Sd/-
(MOHAMMAD ASAD ULLAH, FCS)
Executive Director & Company
Dated: 5 November 2023 Secretary
NOTES:
(1) Shareholders whose names will appear in the Share Register
of the Company or in the Depository Register on the record date
(i.e. 13 November 2023) will be entitled to attend the AGM and to
receive the dividend.
(2) A Member entitled to attend and vote at the AGM may appoint
a Proxy to attend and vote in his/her stead. The Proxy Form, duly
stamped, must be deposited at the Registered office of the Company,
not later than 48 hours before the time fixed for the meeting.
(3) Annual Report for the year 2022-23 will be sent through
e-mail address of the Shareholders and will be available on the
Company website at: www.beximcopharma.com .
(4) The Shareholders will join the virtual AGM through the link
https://bxpharma.bdvirtualagm.com. The Shareholders will be able to
submit their questions/comments and vote electronically 24 (Twenty
four) hours before commencement of the AGM and also during the AGM.
For logging into the system, the Shareholders need to put their
16-digit Beneficial Owner (BO) ID/Folio Number and other credential
as proof by visiting the said link.
(5) We encourage shareholders to login into the system prior to
the meeting. Please allow ample time to login and establish your
connectivity. For any IT related guidance, shareholders may contact
vide email: monir@beximco.ne t or mazibur@beximco.net .
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext.20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUPGCGGUPWGPQ
(END) Dow Jones Newswires
November 06, 2023 07:17 ET (12:17 GMT)
Beximco Pharma (LSE:BXP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Beximco Pharma (LSE:BXP)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024